title: Regulated renin release from 3T3-L1 adipocytes.
abstract: Whereas adipose tissue possesses a local renin-angiotensin system, the synthesis and regulated release of renin has not been addressed. To that end, we utilized differentiating 3T3-L1 cells and analyzed renin expression and secretion. Renin mRNA expression and protein enzymatic activity were not detectable in preadipocytes. However, upon differentiation, renin mRNA and both intracellular and extracellular renin activity were upregulated. In differentiated adipocytes, forskolin treatment resulted in a 28-fold increase in renin mRNA, whereas TNFalpha treatment decreased renin mRNA fourfold. IL-6, insulin, and angiotensin (Ang) II were without effect. In contrast, forskolin and TNFalpha each increased renin protein secretion 12- and sevenfold, respectively. Although both forskolin and TNFalpha induce lipolysis in adipocytes, fatty acids, prostaglandin E(2), and lipopolysaccharide had no effect on renin mRNA or secretion. To evaluate the mechanism(s) by which forskolin and/or TNFalpha are able to regulate renin secretion, a general lipase inhibitor (E600) and PKA inhibitor (H89) were used. Both inhibitors attenuated forskolin-induced renin release, whereas they had no effect on TNFalpha-regulated secretion. In contrast, E600 potentiated forskolin-stimulated renin mRNA levels, whereas H89 had no effect. Neither inhibitor had any influence on TNFalpha regulation of renin mRNA. Relative to lean controls, renin expression was reduced 78% in the epididymal adipose tissue of obese male C57Bl/6J mice, consistent with TNFalpha-mediated downregulation of renin mRNA in the culture system. In conclusion, the expression and secretion of renin are regulated under a complex series of hormonal and metabolic determinants in mature 3T3-L1 adipocytes.
authors.affiliation: Department of Integrative Biology, University of Minnesota, Minneapolis, Minnesota 55455, USA.
authors.forename: Jason D
authors.initials: JD
authors.lastname: Fowler
authors.forename: Nathan D
authors.initials: ND
authors.lastname: Johnson
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Haroldson
authors.forename: Joy A
authors.initials: JA
authors.lastname: Brintnall
authors.forename: Julio E
authors.initials: JE
authors.lastname: Herrera
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Katz
authors.forename: David A
authors.initials: DA
authors.lastname: Bernlohr
mesh_terms: D041721:3T3-L1 Cells; D017667:Adipocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D005576:Colforsin / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D015850:Interleukin-6 / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D008066:Lipolysis / Q000187:drug effects / Q000502:physiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000378:metabolism* / Q000503:physiopathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D012083:Renin / Q000235:genetics* / Q000378:metabolism*; D012084:Renin-Angiotensin System / Q000502:physiology*; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D015850:Interleukin-6; D007546:Isoquinolines; D047428:Protein Kinase Inhibitors; D012333:RNA, Messenger; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D005576:Colforsin; D012083:Renin; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide